Safety and tolerability of exenatide once weekly pooled summary of 1095 patients from DURATION-1, 2 and 3

Introduction: Exenatide once weekly (EQW) provides extended release of exenatide, a GLP-1 receptoragonist, for the treatment of type 2 diabetes (T2DM). Methods: We provide a summary of the accumulated EQW safety based on pooled data from 3 completed randomized controlled trials including 1095 patients followed for 26–30 weeks on either EQW (N=541) or pooled comparators (PC: N=554) treated with sitagliptin, pioglitazone or insulin glargine. Results: Baseline demographics of EQW and PC cohorts were: ˜50% M; age 52–58 y; A1C 8.3–8.5%; BMI 32–33kg/m2. The overall incidence rates (IR) of adverse events (AEs: 77% vs.…